Abstract P4-08-10: Azeliragon (TTP488), an orally- available small molecule RAGE inhibitor, reduces metastasis in preclinical mouse models of breast cancer
Melinda Magna(University of Miami), Barry I. Hudson(Columbia University Irving Medical Center), Philip Miller(University of California San Diego), Marc E. Lippman(Georgetown University), Taekyoung Kwak(Seoul National University), Alec McIntosh(Georgetown University), Masaru Takabatake(Georgetown University), Katherine Drews‐Elger(University of Miami), Barbara Mera(Illinois College)
Cited by 0
Related Papers
BiGG Models: A platform for integrating, standardizing and sharing genome-scale models
|Nucleic Acids Research|2015|1k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Breast Cancer
|New England Journal of Medicine|1992|701
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE–/– mice
|Journal of Clinical Investigation|2008|363